Abstract-Angiotensin II increases and decreases arterial pressure by acting at angiotensin type 1 and type 2 receptors, respectively. Renovascular hypertensive rats exhibit a high level of activity of the peripheral and central renin-angiotensin system. Therefore, in the present study, we evaluated the effect of increasing the expression of angiotensin type 2 receptors in the solitary-vagal complex (nucleus of the solitary tract/dorsal motor nucleus of the vagus), a key brain stem region for cardiovascular regulation, on the development of renovascular hypertension. Holtzman normotensive rats were implanted with a silver clip around the left renal artery to induce 2-kidney 1-clip renovascular hypertension. Three weeks later, rats were microinjected in the solitary-vagal complex with either an adenoassociated virus to increase the expression of angiotensin type 2 receptors or with a control vector. We observed that increasing angiotensin type 2 receptor expression in the solitary-vagal complex attenuated the development of renovascular hypertension and also reversed the impairment of the baroreflex and the increase in the low-frequency component of systolic blood pressure observed in renovascular hypertensive rats. Furthermore, an observed decrease in mRNA levels of angiotensin-converting enzyme 2 in the solitary-vagal complex of renovascular hypertensive rats was restored to control levels after viral-mediated increases in angiotensin type 2 receptors at this site. Collectively, these data demonstrate specific and beneficial effects of angiotensin type 2 receptors via the brain of hypertensive rats and suggest that central angiotensin type 2 receptors may be a potential 
enovascular hypertension, elicited by ≥50% renal artery stenosis or occlusion, affects ≈6% to 8% of the hypertensive population, especially the eldery. 1 Although an increase in renin-angiotensin system (RAS) activity plays a pivotal role in the raised blood pressure observed in the early phase of renovascular hypertension, patients with renal vascular hypertension also exhibit sympathoexcitation, which contributes to the pathogenesis of renovascular hypertension. 2, 3 Animal models of renovascular hypertension were demonstrated ≈80 years ago using the Goldblatt 2-kidney 1-clip (2K1C). 4 These animals also display impaired baroreflexes, [5] [6] [7] an increase in sympathetic nerve activity (SNA), 7, 8 and an overactivity of the RAS. 9, 10 Considering the impairment of the baroreflex and overactivity of the sympathetic nervous system seen in renovascular hypertension, the role of the central nervous system in the development and maintenance of renovascular hypertension has also been demonstrated. 8, 11 There is great interest in understanding the mechanisms underlying the changes in SNA and baroreflexes and for developing therapeutic strategies that will lower blood pressure in hypertensive individuals and animal models of neurogenic hypertension. A major contributor to the changes SNA and baroreflexes is the peptide angiotensin II (Ang II) acting via its neuronal type 1 receptors (AT1R) in cardiovascular control centers in the brain stem and forebrain. 12, 13 Specifically, in the brain stem Ang II acting at AT1R in the nucleus of the solitary tract (NTS) blunts the baroreflex. 12, 14 Because Ang II injection into the NTS also spreads in the dorsal motor nucleus of vagus (DMV), the effects of Ang II in blunting baroreflexes may also involve the DMV.
14 It is also important to point out that, in addition to being the first synaptic relay station in the central nervous system for baroreflex regulation, the NTS plays a part in mediating the high blood pressure and sympathoexcitation seen in spontaneously hypertensive rats. 15, 16 Thus, a potential imbalance between Ang II and constituents of the RAS in the solitary-vagal complex may be involved in the development and maintenance of hypertension, including in the 2K1C Goldblatt model. In fact, we recently demonstrated that NTS overexpression of macrophage migration inhibitory factor, a protein that inhibits the intracellular actions of the AT1R, decreases arterial pressure in spontaneously hypertensive rats. 16 Thus, mechanisms that seem to oppose the actions of Ang II via AT1R may lead to the development of new antihypertensive therapies for people with uncontrolled high blood pressure.
A potential opposing or protective mechanism is the action of Ang II via its type 2 receptors (AT2R). There is evidence that the activation of AT2R can oppose the actions of Ang II via AT1R in the cardiovascular system. 17 AT2R knockout mice exhibit elevated basal blood pressure and a greater sensitivity to the vasopressor effect of Ang II. 18, 19 In addition, coadministration of an AT2R agonist (compound 21) with the AT1R antagonist candesartan induced a greater fall in arterial pressure in spontaneously hypertensive rats when compared with candesartan alone in these animals. 20 Besides these peripheral effects, in vitro studies using cocultures of hypothalamus and brain stem cells demonstrated that AT2R activation stimulates the delayed rectifier K + current, decreasing the excitability of the cells, whereas AT1R activation exerts an opposite effect. 21 Thus, considering that AT2R and AT1R activation exert opposite effects, and the importance of solitary/vagal complex to the regulation of arterial pressure and baroreflex, 22 we investigated whether long-term increased expression of AT2R in the solitary vagal complex (NTS/DMV) of 2K1C rats would affect the development/maintenance of renovascular hypertension. Furthermore, we investigated alterations in the expression of various RAS genes (AT1R, AT2R, and angiotensin-converting enzyme 2 [ACE2]) at the solitary-vagal complex as a potential mechanism for effects of increased AT2R expression on blood pressure. We were particularly interested in ACE2 because it is known that the ACE2/angiotensin-(1-7)/Mas receptor axis is a cardioprotective arm of the RAS, 23 and chronic activation of AT2R in peripheral tissues activates ACE2. 24 In addition, overexpression of the human form of this enzyme in the paraventricular nucleus of hypothalamus impaired the development of Ang II-induced hypertension, 25 and the increase in SNA observed in mice with chronic heart failure was reduced in transgenic mice with overexpression of human ACE2 in the NTS and rostral ventrolateral medulla (RVLM).
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Methods
Detailed descriptions of the animal subjects and all experimental methods are included in the online-only Data Supplement. Given below are the experimental protocols used.
Experiment 1
Two months after adeno-associated virus serotype 2 (AAV2)-chicken β-actin promoter (CBA)-AT2R or AAV2-CBA-enhanced green fluorescent protein (eGFP) were injected into the NTS/DMV of naïve male Sprague-Dawley rats (n=3), animals were deeply anesthetized, perfused transcardially, and the brain stem was processed for AT2R autoradiography as described in the online-only Data Supplement.
Experiment 2
Male Holtzman rats (n=5-6 per group) underwent 2K1C surgery and implantation of telemetry transducers, and 21 days later animals received microinjections of either AAV2-CBA-eGFP or AAV2-CBA-AT2R into the NTS/DMV. Mean arterial pressure (MAP) and heart rate were recorded continuously, for a 24-hour period, 18 and 3 days before vector injection, and 7, 14, 21, 26, and 31 days after vector injection. Rats were euthanized at 31 days after vector injection, brain stems were removed, cut, and mounted on slides to check the eGFP fluorescence in the NTS/DMV and to indicate NTS/DMV injection site.
Experiment 3
Male Holtzman rats (n=8-9 per group) underwent sham or 2K1C surgery. This was followed, 21 to 24 days later, by microinjections of either AAV2-CBA-eGFP or AAV2-CBA-AT2R into the NTS/DMV. In 2K1C rats, the systolic arterial pressure was monitored for 3 weeks by tail cuff starting 1 week after the surgery. Only animals with an increase in systolic arterial pressure after 3 weeks of the 2K1C surgery underwent virus injection in the NTS/DMV. We will refer to Holtzman rats with sham 2K1C surgery as normotensive rats. Four weeks after the viral transduction, rats were implanted with 2 catheters: one into the abdominal aorta through the femoral artery for direct recordings of MAP and heart rate and another into the femoral vein for drug administration. The next day, MAP and heart rate were recorded in conscious rats, followed by the analysis of baroreflex function as described in the Methods in the online-only Data Supplement. The day after these tests, rats were deeply anesthetized, decapitated, and the brains were collected for quantitative reverse transcription polymerase chain reaction analyses of AT1R, AT2R, and ACE2 mRNAs in the NTS/DMV, and the kidneys were weighed.
Results
Viral-Mediated Expression of GFP and AT2R in the NTS/DMV
AT2R autoradiography was performed as described in experiment 1 to verify the effectiveness of AAV2-CBA-AT2R in inducing increased AT2R expression in the NTS/DMV. As shown in the representative autoradiograms in Figure 1A to 1D, there is intense AT2R-specific binding in the NTS/DMV of an AAV2-CBA-AT2R-injected rat ( Figure 1A ) when compared with the NTS/DMV of an AAV2-CBA-eGFPinjected rat ( Figure 1B) . Figure 1C and 1D shows similar levels of AT1R-specific binding in the NTS/DMV of AAV2-CBA-AT2R-injected and AAV2-CBA-eGFP-injected rats, respectively. Quantification of the autoradiographic data demonstrated that in the eGFP-transduced rats, AT2R levels are lower in the NTS/DMV when compared with the inferior olivary nucleus but significantly increase only in the NTS/DMV after AT2R transduction (F(2,6)=46.89; P<0.01; Figure 1E ). AT2R transduction in the NTS/DMV did not change AT1R levels at this site ( Figure 1E ). The representative fluorescence micrographs presented in Figure 1F show eGFP expression at 3 rostro-caudal levels of the solitary-vagal complex, from bregma, 31 days after microinjection of AAV2-CBA-eGFP as described in experiments 2 and 3. Quantitative reverse transcription polymerase chain reaction analyses, after microinjections of either AAV2-CBA-eGFP or AAV2-CBA-AT2R into the NTS/DMV as described in experiment 3, showed that the AT2R vector was effective in increasing AT2R levels in the NTS/DMV ( Figure 4A ).
Increasing AT2R Expression in the NTS/DMV Attenuates the Development of 2K1C Hypertension
The effects of increasing AT2R expression in the NTS were studied as described in the Methods, Experiment 2 section of this article. Baseline levels of MAP (18 days before vector injections) were similar in rats assigned to the AT2R or eGFP groups during the light (AT2R, 101±2 and eGFP, 103±5 mm Hg) and dark periods (AT2R, 112±4 and eGFP, 111±5 mm Hg). At 3 days before vector injections (21 days after 2K1C surgery), rats assigned to the AT2R and eGFP groups exhibited an increase in their MAP when compared with baseline levels in the light period (AT2R, 134±3 and eGFP, 130±9 mm Hg versus respective baselines; F (1, 63) Figure 2A and 2B). In 2K1C-AT2R rats, the development of hypertension was potently attenuated when compared with the 2K1C-eGFP animals during both light (2K1C-AT2R, 154±7 versus 2K1C-eGFP, 179±11 mm Hg at day 31; P<0.05) and dark periods (2K1C-AT2R, 158±6 versus 2K1C-eGFP, 195±5 mm Hg at day 31; P<0.05; Figure 2A and 2B). There were no significant differences in heart rate between 
Baroreflex Impairment and Increased Low Frequency of Systolic Blood Pressure in 2K1C Rats Are Restored After Increasing AT2R Expression in the NTS/DMV
Baseline MAP levels of the animals that underwent baroreflex tests are shown in Figure 3A . The data indicate that the high levels of baseline MAP that occur in the 2K1C-eGFP group were significantly reduced in the 2K1C-AT2R ( Figure 3A ; F(1,31)=64.841; P<0.001). We also observed that the ratio of the left kidney:right kidney weight in 2K1C rats was decreased when compared with that observed in normotensive rats, as demonstrated previously, 27 and there were no differences between the eGFP-and AT2R-treated groups (Table) . In contrast to the 2K1C animals, there was no change in MAP after AT2R vector injection into the NTS/DMV in normotensive rats ( Figure 3A ).
Baroreflexes were assessed using a dose of phenylephrine that elicits a pressor response and a dose of sodium nitroprusside that causes a depressor effect as described in the Methods, Experiment 3 section of this article (online-only Data Supplement). The 2K1C-eGFP rats displayed an impairment of baroreflex function (2K1C-eGFP slope, −0.95±0.05 versus normotensive-eGFP slope, −1.37±0.06 bpm/mm Hg; F (3, 31) =6.175; P<0.05; Figure 3B ). Importantly, in 2K1C-AT2R rats, the baroreflex function was restored (slope, −1.45±0.07 bmp/mm Hg) to the levels observed in normotensive rats (normotensive-AT2R slope, −1.56±0.07 and normotensive-eGFP slope, −1.37±0.06 bpm/mm Hg; Figure 3B ).
Using spectral analysis of systolic blood pressure (SBP), we observed that the low frequency (LF) of SBP, an index of vasomotor sympathetic activity, was significantly higher in the 2K1C-eGFP-transduced rats ( Figure 3C ). LF and high frequency (HF) of pulse interval (PI) were not different among the groups ( Figure S1 in the online-only Data Supplement) although there was a tendency for LF of PI to increase and for HF of PI to decrease in the 2K1C-eGFP group. Indeed, when the LF/HF ratio is calculated, a higher ratio was found in 2K1C-eGFP (0.23±0.024 versus other groups; P<0.05), probably because of a combination of higher LF and decreased HF of PI in these animals ( Figure S1 )
Reduced ACE 2 mRNA Levels in the NTS/DMV of 2K1C Rats Are Restored in the AAV2-CBA-AT2R-Injected Rats
As expected, the normotensive-AT2R and 2K1C-AT2R groups displayed a higher level of AT2R mRNA in the NTS when compared with the eGFP-injected rats (normotensive-AT2R, 0.45±0.13 and 2K1C-AT2R, 0.425±0.9 A, Increased AT2R expression in the NTS/DMV decreases mean arterial pressure in 2K1C rats but not in normotensive (NT) rats. B, Baroreflex function curves from 2K1C and NT rats. Grouped heart rate (HR) baroreflex slopes in response to each 10 mm Hg change in MAP produced by phenylephrine (pressor) or sodium nitroprusside (depressor) as described in the Methods in the online-only Data Supplement. C, Power of SBP spectra at the LF band. Results in A and C are presented as mean±SEM; NT-eGFP, n=8; NT-AT2R, n=9; 2K1C-eGFP, n=9; 2K1C-AT2R, n=9. *P<0.05 vs respective treatment in NT rats; #P<0.05 vs 2K1C-eGFP; &P<0.05 vs all groups. Figure 4A ). However, AT2R overexpression did not influence AT1R mRNA levels (F(3,14)=0.750; P>0.05; Figure 4B ). The 2K1C-eGFP rats displayed decreased levels of ACE2 mRNA in the NTS/DMV when compared with the normotensive rats (0.037±0.014, versus other groups; F (3, 15) =7.775; P<0.05). Interestingly, the lower levels of ACE2 mRNA found in 2K1C-eGFP were restored in 2K1C-AT2R rats to those observed in the normotensive rats (2K1C-AT2R, 0.314±0.076 versus normotensiveeGFP, 0.232±0.037 and normotensive-AT2R, 0.180±0.0304; P>0.05; Figure 4C ).
Discussion
The role of the RAS and particularly AT1R in the development and maintenance of renovascular hypertension is well established. 9, 10, 28 In addition to the peripheral RAS, higher levels of Ang II and AT1R are present in different brain areas in 2K1C hypertensive rats, including in the paraventricular nucleus in the hypothalamus and the RVLM in the brain stem, 8, 29, 30 suggesting that the central RAS has a pivotal role in the development/maintenance of hypertension of the 2K1C model. In contrast to the established role of central and peripheral AT1R, in renovascular hypertension, to date there have been no studies implicating a role of central AT2R in this form of high blood pressure. In fact, studies from mice suggested that AT2R do not have a counter-regulatory effect against the hypertensive action of Ang II acting via AT1AR in 2K1C hypertension. 28 In contrast, the present study has demonstrated, unequivocally and for the first time, an effect of AT2R in the solitary-vagal complex, a brain stem region that is important in the control of arterial pressure and for the development and maintenance of renovascular hypertension. Our current data demonstrate that increased expression of AT2R in the solitary-vagal complex attenuates the increase in arterial pressure observed in 2K1C rats.
In the past decade, studies have begun to shed light on the role of AT2R in cardiovascular control. 17 Despite low levels of endogenous AT2R in several brain stem areas of adult rats, including the NTS/DMV as demonstrated in the present study and others, 31 functional data indicate that central AT2R can influence blood pressure. Specifically, chronic intracerebroventricular infusion of the selective AT2R agonist Compound 21 reduced arterial pressure and norepinephrine excretion in normotensive rats, suggesting that SNA has been decreased. 32 Another study from the same group 33 demonstrated that adenoviral-mediated increases in the expression of AT2R in the RVLM of normotensive rats elicited a reduction in nocturnal MAP and norepinephrine excretion, and an increase in urine excretion, possibly as a result of sympathoinhibition. This effect of AT2R overexpression on arterial pressures of normotensive rats seems to be specific for the RVLM because in the present study 30 days after AT2R transduction in the NTS/DMV of normotensive rats, there was no change in MAP ( Figure 3A) .
It is well established that the baroreflex is attenuated in 2K1C rats, and impairment of the baroreflex seems to be critical in the development and maintenance of 2K1C hypertension 5-7 because a reduction in the baroreflex gain might also contribute to the increase in sympathetic outflow and high blood pressure. 34 Evidence suggests that in 2K1C rats Ang II acting via its AT1R in the NTS is responsible for dampening the baroreflexes in renovascular hypertension. For example, circulating Ang II levels are high, especially during phase I (first 4 weeks) of 2K1C renovascular hypertension, 9,10 and Ang II acting at AT1R within the NTS has been reported to attenuate baroreflex function. 12, 14 Similar to the findings in the present study, Oliveira-Sales et al 7 demonstrated that during phase I of 2K1C hypertension, there is an impairment of the baroreflex, and this may be related to the high levels of Ang II.
The present study demonstrated, in a striking manner, that after increasing AT2R expression in the solitary-vagal complex of 2K1C rats, baroreflex function was restored to control levels. The mechanism involved in the restoration of the baroreflex remains to be determined, but it may involve the ACE2/angiotensin-(1-7)/Mas receptor axis based on the following evidence. ACE2 has high catalytic activity to convert Ang II to angiotensin-(1-7), 35 and this enzyme is present in rat NTS as observed previously 36 and also in the present study. Angiotensin-(1-7) has been shown to increase baroreflex sensitivity in the NTS, 37 and overexpression of human ACE2 in the NTS and RVLM of mice enhances baroreflex function. 26 Conversely, microinjection of an ACE2 inhibitor into the NTS decreased baroreflex sensitivity. 38 In the present study, we observed a significant decrease in ACE2 mRNA levels in the solitary-vagal complex of 2K1C-eGFP rats but not in the 2K1C-AT2R animals. Thus, it is possible that in the 2K1C-eGFP rats, the observed decrease in baroreflex sensitivity and altered sympathovagal balance (indicated by the ratio of LF:HF of PI) was because of an imbalance of ACE2 in the solitary-vagal complex. Restoring the levels of ACE2 (and therefore angiotensin-(1-7)) via overexpression of AT2R at the NTS/DMV may have ameliorated the loss of baroreflex function and the altered sympathovagal balance normally seen in 2K1C rats, consequently reducing their hypertension. In accordance with this idea, Ali et al 24 demonstrated that CGP42112A, an AT2R agonist, increase the expression of ACE2 and Mas receptors in the HK-2 cell line. In vivo data, in the same study, demonstrated that the lower expression levels and the activity of ACE2 in obese Zucker rats were restored after 2 weeks treatment with CGP42112A. Therefore, it seems that the activation of AT2R leads to an increase in ACE2 expression, similar to that observed in the present study. However, the molecular mechanisms involved in the regulation of ACE2 mRNA expression in the NTS by AT2R levels are yet to be determined.
In addition to the baroreceptor impairment in 2K1C rats, another mechanism that could account for the hypertension in 2K1C rats is the increase in SNA observed in these animals. 7, 8 It has been reported that NTS inhibition reduces arterial pressure and SNA in spontaneously hypertensive rats. 15 Although we have not directly measured SNA, we observed that in 2K1C-eGFP, there was an increase in LF of SBP. Because LF of SBP is an index of vasomotor sympathetic activity, it is possible that AT2R overexpression in the NTS/DMV induced a decrease in the sympathoexcitation in 2K1C rats. As pointed out earlier in the discussion, MAP did not totally recover to normotensive values after AT2R overexpression in the NTS/DMV. Viral transduction was made between phases I and II (5-8 weeks) of 2K1C hypertension. 10 In phase II, both SNA and MAP are increased by volume retention, decreased sodium excretion, and an increase in Ang II sensitivity. 7,9,10 all of which might be not directly affected by the AT2R overexpression in the solitary-vagal complex.
In conclusion, the current results indicate that increased expression of AT2R within the NTS/DMV of 2K1C rats impairs the full development of hypertension in these animals. The restoration of baroreflex function and an increase of LF of SBP produced by increased AT2R expression are associated with increased ACE2 mRNA levels in the solitary-vagal complex, and this may be an important mechanism that contributed to these responses.
Perspectives
Despite a variety of treatment regimens hypertension, and in particular high blood pressure associated with enhanced sympathetic outflow, remains a worldwide problem. Although it is well known that sympathoexcitation is involved in renovascular hypertension, the underlying mechanisms including a role for AT2R, and whether they antagonize AT1R actions in central nervous system cardiovascular control centers, are yet to be established. The current study demonstrates that increasing AT2R expression in the solitary-vagal complex exerts a profound attenuation of the development of renovascular hypertension and restores baroreflex function and sympathetic modulation of arterial pressure to normal values in 2K1C rats. As such, the present data demonstrate a specific and beneficial effect of AT2R in a central nervous system cardiovascular control center and suggest that AT2R may be a potential target for therapeutics in hypertension that involves enhanced sympathetic outflow/impaired baroreflex function. Whether this beneficial action of AT2R is a specific antagonism of AT1R effects in the NTS/DMV or simply an opposing effect remains to be determined.
• Increased AT2R expression in the nucleus of the solitary tract/dorsal motor nucleus of vagus of 2K1C rats also restored baroreflex function and sympathetic modulation of arterial pressure to normal in 2K1C rats.
• These beneficial effects of AT2R in 2K1C rats are associated with increased expression of angiotensin-converting enzyme 2 mRNA at the nucleus of the solitary tract/dorsal motor nucleus of vagus.
What Is Relevant?
• AT2R exerts opposite effects when compared with angiotensin II via its AT1R.
• Increasing AT2R levels in the nucleus of the solitary tract/dorsal motor nucleus of vagus may be a mechanism that can be targeted as a potential antihypertensive strategy.
Summary
Increased expression of AT2R within the solitary-vagal complex of 2K1C rats impairs the full development of hypertension in these animals and restores the baroreflex function and the sympathetic modulation of the systolic blood pressure to normal values. The normalization of angiotensin-converting enzyme 2 mRNA levels in the solitary-vagal complex after AT2R overexpression might be an important mechanism for these beneficial effects of AT2R. 
Novelty and Significance
